- About Us
- Nano-Social Network
- Nano Consulting
- My Account
Harris & Harris Group invests $2,800,000 in Evolved Nanomaterial Sciences, Inc.
Posted on March 09, 2006
Harris & Harris Group, Inc., announced today that it led a
$3,300,000 Series A round of financing of privately held Evolved
Nanomaterial Sciences, Inc. (ENS) of Cambridge, MA. Harris &
Harris Group invested $2,800,000 in this round of financing.
ENS has developed a number of nanotechnology-enhanced approaches for the resolution of chiral molecules. ENS is using its proprietary ESPTM technology to manufacture high-capacity, high-generality HPLC columns that simplify chiral method development and chiral chromatography and purification. The A round funding will be used to fill out its manufacturing and product development capabilities and to support the launch of its first line of commercially available products.
Harris & Harris Group is a publicly traded venture capital company that now makes initial investments exclusively in tiny technology, including nanotechnology, microsystems and microelectromechanical systems (MEMS). The Company's last 27 initial private equity investments have been in tiny technology-enabled companies. The Company has 20,756,345 common shares outstanding.
Detailed information about Harris & Harris Group and its holdings can be found on its website at www.TinyTechVC.com.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
Arrowhead Provides Response to New Minority Shareholder Announcement January 7th, 2017
Harris & Harris Group Announces a Proposed Strategic Restructuring December 20th, 2016
Dream Chip Technologies Presents First 22nm FD-SOI Silicon of New Automotive Driver Assistance SoC: Advanced driver assistance system (ADAS) computer vision SoC developed for European THINGS2DO project with working first silicon fabricated on GLOBALFOUNDRIES’ 22nm FD-SOI Platfor February 27th, 2017
New nano approach could cut dose of leading HIV treatment in half February 24th, 2017